A multiple ascending dose study of the safety, pharmacokinetics, and pharmacodynamics of LXR-623 administered orally to healthy subjects

Trial Profile

A multiple ascending dose study of the safety, pharmacokinetics, and pharmacodynamics of LXR-623 administered orally to healthy subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2007

At a glance

  • Drugs LXR 623 (Primary)
  • Indications Atherosclerosis
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 20 Sep 2007 In September 2007, Wyeth discontinued development of LXR 623, as it had an unfavourable proflie for further development.
    • 22 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top